Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer
Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.
Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand
February 11th 2020Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.
Targeted Therapy, Immunotherapy Are Replacing Chemotherapy in Endometrial Cancer
Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.
Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian Cancer
Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.